BioNTech SE to Post Q1 2024 Earnings of $1.26 Per Share, HC Wainwright Forecasts (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) – Stock analysts at HC Wainwright issued their Q1 2024 EPS estimates for BioNTech in a research note issued on Wednesday, April 17th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of $1.26 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $107.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2024 earnings at ($1.99) EPS, Q3 2024 earnings at ($2.22) EPS, Q4 2024 earnings at $0.79 EPS and FY2024 earnings at ($2.15) EPS.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion.

A number of other research firms have also recently issued reports on BNTX. Canaccord Genuity Group restated a “buy” rating and set a $171.00 price target on shares of BioNTech in a report on Thursday, March 21st. The Goldman Sachs Group decreased their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. JPMorgan Chase & Co. dropped their price objective on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research note on Friday, March 22nd. UBS Group decreased their target price on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research report on Wednesday, March 27th. Finally, BMO Capital Markets dropped their price target on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a research report on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Stock Performance

NASDAQ BNTX opened at $88.01 on Monday. The stock has a fifty day simple moving average of $91.09 and a 200 day simple moving average of $96.98. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $20.92 billion, a price-to-earnings ratio of 21.36 and a beta of 0.23. BioNTech has a twelve month low of $85.21 and a twelve month high of $125.83.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently bought and sold shares of the company. Harding Loevner LP purchased a new position in BioNTech in the 4th quarter valued at approximately $410,984,000. Baillie Gifford & Co. lifted its holdings in BioNTech by 15.5% during the 3rd quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock worth $934,612,000 after purchasing an additional 1,152,541 shares in the last quarter. Clearbridge Investments LLC grew its holdings in BioNTech by 41.6% during the 3rd quarter. Clearbridge Investments LLC now owns 484,126 shares of the company’s stock valued at $52,595,000 after buying an additional 142,344 shares in the last quarter. Primecap Management Co. CA grew its holdings in BioNTech by 2.8% during the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after buying an additional 131,490 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in shares of BioNTech by 43.1% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock valued at $44,610,000 after buying an additional 127,951 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.